Editing Bone marrow suppression (section)

===Chemotherapy induced myelosuppression===
Bone marrow suppression due to anti-cancer chemotherapy is much harder to treat and often involves hospital admission, strict infection control, and aggressive use of intravenous [[antibiotics]] at the first sign of infection.<ref>{{Cite journal
|last1=Al Sudairy|first1=Reem
|last2=Alzahrani|first2=Mohsen
|last3=Alkaiyat|first3=Mohammad
|last4=Alshami|first4=Mona
|last5=Yaqub|first5=Abdullah
|last6=Al Fayadh|first6=Maha
|last7=Al-Surimi|first7=Khaled
|last8=Jazieh|first8=Abdul Rahman
|date=2019-08-01
|title=Improving Door-to-Antibiotic Administration Time in Patients With Fever and Suspected Chemotherapy-Induced Neutropenia: A Tertiary Care Center Experience
|url=https://meridian.allenpress.com/innovationsjournals-JQSH/article/2/3/78/434843/Improving-Door-to-Antibiotic-Administration-Time
|journal=Global Journal on Quality and Safety in Healthcare|language=en|volume=2|issue=3|pages=78–84|doi=10.4103/JQSH.JQSH_1_19
|s2cid=181784553
|issn=2666-2353|doi-access=free}}</ref>

[[G-CSF]] is used clinically (see [[Neutropenia]]) but tests in mice suggest it may lead to bone loss.<ref name=Dec2006>[http://news.wustl.edu/news/Pages/8512.aspx "Researchers urge monitoring of bone health during chemotherapy"].</ref><ref name="pmid17192391">{{Cite journal
|vauthors=Hirbe AC, Uluçkan O, Morgan EA, Eagleton MC, Prior JL, Piwnica-Worms D, Trinkaus K, Apicelli A, Weilbaecher K
|title=Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner
|journal=Blood|volume=109|issue=8|pages=3424–31|date=April 2007
|pmid=17192391|pmc=1852257|doi=10.1182/blood-2006-09-048686}}</ref>

[[GM-CSF]] has been compared to G-CSF as a treatment of chemotherapy-induced myelosuppression/[[Neutropenia]].<ref name="pmid9679526">{{Cite journal |author=Beveridge RA
|title=A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression
|journal=Cancer Invest.|volume=16|issue=6|pages=366–373|year=1998
|pmid=9679526|doi=10.3109/07357909809115775
|author2=Miller JA
|author3=Kales AN
|last4=Binder|first4=Richard A.
|last5=Robert|first5=Nicholas J.
|last6=Harvey|first6=Jimmie H.
|last7=Windsor|first7=Kevin
|last8=Gore|first8=Ira
|last9=Cantrell|first9=James}}</ref>

[[Trilaciclib|Trilaciclib (COSELA)]], a [[CDK inhibitor|CDK4/6 inhibitor]], is administered before [[chemotherapy]] in [[Small-cell carcinoma|small cell lung cancer]] to control chemotherapy-induced myelosuppression. <ref>{{Cite web|last=Commissioner|first=Office of the|date=2021-02-12|title=FDA Approves Drug to Reduce Bone Marrow Suppression Caused by Chemotherapy|url=https://www.fda.gov/news-events/press-announcements/fda-approves-drug-reduce-bone-marrow-suppression-caused-chemotherapy|archive-url=https://web.archive.org/web/20210212221033/https://www.fda.gov/news-events/press-announcements/fda-approves-drug-reduce-bone-marrow-suppression-caused-chemotherapy|url-status=dead|archive-date=February 12, 2021|access-date=2021-11-04|website=FDA|language=en}}</ref>